

Executive Corridor  
Darlington Memorial Hospital  
Hollyhurst Road  
Darlington  
DL3 6HX  
Switchboard Tel: 01325 38 0100  
Foundation Trust Office: 01325 74 3625  
Corporate Records Office: 01325 74 3700

Request for Information Reference: 02.22.17

FOI Direct line: 01325 743700  
Email: [cdda-tr.cddftfoi@nhs.net](mailto:cdda-tr.cddftfoi@nhs.net)

Email only

25<sup>th</sup> April 2022

## **Freedom of Information Act 2000 – Request for Information**

Thank you for submitting a request for information which we received on 8<sup>th</sup> April 2022 in relation to County Durham and Darlington NHS Foundation Trust (the Trust). Your request has been processed under the provisions of the Freedom of Information Act 2000 and I am now able to provide you with a response.

Your request was in relation to patient treatment with Nivolumab and I am providing the following information in response to your specific questions:

- 1. In the last 3 months, how many patients have been initiated\* on the following agents for treatment for melanoma?**
  - Nivolumab (monotherapy)
  - Nivolumab AND Ipilimumab (combination)

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
- 2. In the last 3 months, how many patients have been initiated\* on the following agents for treatment for Renal Cell Carcinoma?**
  - Nivolumab (monotherapy)
  - Nivolumab + Ipilimumab
  - Nivolumab + Cabozantinib
  - Avelumab + Axitinib

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.
- 3. In the past 3 months, how many patients have been initiated\* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:**
  - Nivolumab (monotherapy)

- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**

**\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

The Trust does not treat skin cancer patients with chemotherapy or immunotherapy on any of our sites. For further information we advise you to contact either South Tees NHS Foundation Trust or The Newcastle Upon Tyne Hospitals NHS Foundation Trust. If you wish to contact them in accordance with Section 16 of the Act (duty to provide advice and assistance) you can contact them via the following postal addresses:

South Tees NHS Foundation Trust:  
Murray Building  
The James Cook University Hospital  
Marton Road  
Middlesbrough, TS4 3BW

The Newcastle Upon Tyne Hospitals NHS Foundation Trust  
Freeman Road  
Newcastle Upon Tyne, NE7 7DW

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log on the Trust's website. However please be assured that we anonymise all responses prior to adding them to the disclosure log.

I hope that this response has provided you with the information you had requested. If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me by telephone or in writing. If however, you are dissatisfied with the way in which your request has been handled and would like an internal review, you will need to contact me in writing at the above address or via [cdda-tr.cddftfoi@nhs](mailto:cdda-tr.cddftfoi@nhs).

If you remain dissatisfied with our response following an internal review you have the right to appeal to The Information Commissioner at Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. More information is available on their website; [www.ico.gov.uk](http://www.ico.gov.uk).

Yours sincerely

**Corporate Records and Freedom of Information Facilitator**